CSPC Innovation

CSPC INNOVATION PHARMACEUTICAL CO., LTD. (formerly CSPC Xinyu Pharmaceutical Co., Ltd., hereinafter referred to as "CSPC Innovation") is a subsidiary of CSPC Group (Stock Code: 1093.HK), a constituent stock of the Hang Seng Index in Hong Kong. It has developed into an innovative company integrating biopharmaceuticals, active pharmaceutical ingredients, and functional foods. Relying on the innovative platforms of Jushi Biotechnology and CSPC Group, CSPC Innovation will make breakthroughs in cutting-edge fields such as antibody drugs, antibody-drug conjugates (ADCs), and mRNA vaccines. It has successfully launched China's first mRNA vaccine, the biosimilar of茁乐® (Omalizumab for Injection), which was the first drug developed under Category 3.3 of therapeutic biological products in China, and the first-in-class biological new drug PD-1 inhibitor恩舒幸®. CSPC Innovation's main products include caffeine, acarbose, anhydrous glucose raw materials, Guowei Kang Vitamin C tablets, and B-complex vitamin tablets. Among them, the production scale and market share of caffeine rank at the top globally, making it a global supplier to three major international beverage companies: PepsiCo, Coca-Cola, and Red Bull. The company is also among the top tier in China's health food industry, having created the highly popular Vitamin C tablet brand Guowei Kang. Currently, CSPC Innovation has gained recognition in the global market. Its products have been certified by GMP, ISO, BRC, KOSHER systems, and through a well-established overseas sales network, they are distributed across multiple markets including North America, South America, Europe, and South Asia, reaching numerous countries and regions worldwide. Meanwhile, the company has established a sustainable development management system and actively engages in carbon inventory, carbon auditing, carbon footprint, and related initiatives, earning a silver medal in the Ecovadis rating system. As an innovative company, CSPC Innovation will continue to adhere to research and development-driven growth in the future, with biopharmaceuticals and functional foods (raw materials) as its two core pillars. It will deepen its focus on the broader health sector, striving to enhance the core competitiveness of China’s biopharmaceutical industry on the international stage and contribute to improving the overall health level of the Chinese population.